Ketamine for anxiety: all studies (page 2)

Effects of sub-anesthetic doses of esketamine on immune function and postoperative negative emotions in acoustic neuroma patients: a randomized clinical trial.

Annals of medicine July 3, 2026 Zheping Chen, Yaozhu Wang, Peilin Cong et al.

Patients undergoing acoustic neuroma (AN) surgery often experience postoperative negative emotions, including anxiety, depression, and immune function suppression. This trial evaluated whether perioperative sub-anesthetic esketamine improves early postoperative negative emotions and immune function. In this single-center, double-blind, randomized trial, 84 patients scheduled for AN surgery were...

DOI: 10.1080/07853890.2026.2692804 Full text Esketamine Anxiety Depression Negative emotion +1

Mystical Experiences as Catalysts in Ketamine-Assisted Psychotherapy: A Case Study

Journal of Psychoactive Drugs July 3, 2026 Miguel Joaquim Soares Teles Couceiro, Victor José da Conceição Teixeira Amorim Rodrigues, Nuno Manuel Correia Torres

This case study explores the potential role of mystical-type experiences in ketamine-assisted psychotherapy (KAP). A patient with generalized anxiety disorder and migraines underwent four intramuscular KAP sessions (0.5-0.9 mg/kg). Outcomes were assessed using the Outcome Questionnaire-45 (OQ-45), the Hood Mysticism Scale (HMS), and interviews. Greater therapeutic gains followed sessions with...

DOI: 10.1080/02791072.2026.2696253 Mysticism Anxiety disorder Therapeutic relationship Outcome game theory +4

N,N-dimethyltryptamine elicits antidepressant and anxiolytic effects in helpless mice: a comparative study with S-ketamine.

Neuropharmacology July 1, 2026 Anne Nathalia De Sousa-Silva, Clarissa de Almeida Moura, Carina Ioná De Oliveira Torres et al. 1 citation

N,N-dimethyltryptamine (DMT) is an naturally occurring indoleamine with hallucinogenic and antidepressant effects in humans. Here, we compared the effects of DMT and S-ketamine, a fast-acting antidepressant, in helpless mice. To induce helplessness, male single and group-housed mice were exposed to inescapable footshock stress; only helpless animals were subsequently treated with S-ketamine 10...

DOI: 10.1016/j.neuropharm.2026.110947 Full text Anxiety Depression Animal models Mouse +2

Effects of Esketamine on EEG temporal dynamics in patients with depression

UNC Libraries June 21, 2026 Verina Guirguis

Esketamine is an effective rapid-acting pharmacological intervention for treatment-resistant depression. However, the temporal dynamics of underlying brain networks associated with the improvement of depressive symptoms remain elusive. This observational study seeks to delineate alteration in network activity within 90 minutes of nasal Esketamine administration, with a focus on exploring its...

DOI: 10.17615/b350-9s23 Major depressive disorder Anxiety Treatment-resistant depression Depression economics +9

At-Home Telehealth-Supported Subcutaneous Ketamine Therapy in Adults With Moderate to Severe Depression, Anxiety, or PTSD: A Real-World Observational Study of Safety, Feasibility, and Clinical Outcomes in a Large, Heterogeneous Cohort in the United States.

Journal of Medical Internet Research June 17, 2026 Acacia C Parks, Amanda L Woodward, Robert D Henry et al.

Background: Depression, anxiety,, and PTSD are leading global causes of disability. Standard interventions utilize slow mechanisms of action, high attrition, and significant accessibility barriers. While intravenous (IV) and intranasal ketamine are rapid-acting alternatives, high cost and intensive logistical requirements limit adoption. Sublingual (SL) at-home ketamine addresses some gaps but...

DOI: 10.2196/92647 Full text

Intranasal esketamine in treatment-resistant depression with and without comorbid borderline personality disorder: A multicenter real-world longitudinal study.

Psychiatry Research June 16, 2026 Filippo Mazzoni, Fabiola Raffone, Arianna De Ciechi et al.

Borderline personality disorder (BPD) often occurs alongside treatment-resistant depression (TRD), but the impact of BPD on real-world outcomes with intranasal esketamine is unclear. Consecutive TRD outpatients initiating intranasal esketamine treatment at four Italian centres between 1 September 2024 and 30 September 2025 were enrolled in the study (n = 90): 45 with comorbid BPD and 45 without...

DOI: 10.1016/j.psychres.2026.117288 Full text Anxiety Esketamine Treatment-resistant depression Borderline personality disorder +2

Telehealth-supported ketamine for depression and anxiety: A systematic review.

Australasian Psychiatry June 11, 2026 Eden Mane, Saras Mane

ObjectivesTo systematically review the effectiveness, safety, and care models of telehealth-supported ketamine for depression and/or anxiety in adults and consider implications for Australasian clinical practice.MethodsFollowing PRISMA 2020, we searched for randomised or observational studies of adults receiving at-home telehealth-supported ketamine for depression and/or anxiety, to August...

DOI: 10.1177/10398562261458880 Full text Anxiety Depression Ketamine Telehealth

Ketamine/esketamine pharmacotherapy for treatment of anxiety disorders and anxiety symptoms in depression: Systematic review.

Journal of Psychopharmacology June 2026 Vasilios G Masdrakis, Zoe Tebbs, Vasilios Natsis et al.

Ketamine and esketamine ("es/ketamine") treatment protocols have been investigated in patients' samples with treatment-refractory anxiety disorders. We systematically reviewed publications in which es/ketamine was used to treat anxiety symptoms in the context of either Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) anxiety disorders or treatment-resistant...

DOI: 10.1177/02698811251389583 Full text Esketamine Anxiety disorders Anxious depression Treatment-refractory anxiety

The effect of the Apollo Neuro device on anxiety among participants who underwent ketamine assisted therapy: A non-randomized, observational cohort study

European Psychiatry June 1, 2026 S. Wong, V. Tsang, Brendan Tao et al.

Introduction Positive feedback from a mental health treatment program that uses treatment adjuncts inspired researchers to assess the potential role of the Apollo Neuro device in mental health outcomes. Objectives To assess the impact of the Apollo Neuro device on anxiety levels in a ketamine-assisted therapy treatment program, comparing those using the device with those not using the device....

DOI: 10.1192/j.eurpsy.2026.11223

Longitudinal Assessment of Ketamine-Assisted Community of Practice Therapy: A Retrospective 5-Year Study on Depression, Anxiety and PTSD

European Psychiatry June 1, 2026 A. Kuzma-Hunt, Z. Hamadeh, V. Tsang

Introduction Ketamine-assisted therapy shows rapid benefit in treatment-resistant depression, anxiety, and PTSD (Walsh et al. BJPsych Open 2022;8:e19). The Roots to Thrive Ketamine assisted Therapy (RTT-KaT) program is a unique 12-week program that combines 12 Community of Practice (group therapy) sessions and three ketamine medicine sessions (Tsang et al. Ther Adv Psychopharmacol...

DOI: 10.1192/j.eurpsy.2026.11732